 | • レポートコード：MRC2303L048 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、220ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査資料によると、乳がん診断の世界市場規模は2021年に5,685.81百万ドル、2022年に6,129.25百万ドルとなり、その後CAGR 7.97％で成長して2027年までに9,010.75百万ドルに到達する見通しです。本書では、世界の乳がん診断市場について多面的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、技術別分析（画像検査、分子検査、組織生検検査）、がん種類別分析（BRCA乳がん、EGFR変異検査乳がん、ER＆PR乳がん、HER2乳がん）、コンポーネント別分析（消耗品、器具）、エンドユーザー別分析（診断検査室、病院＆外来手術センター、研究・学術機関）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの項目をまとめています。なお、本書には、Abbott Laboratories、Agilent Technologies, Inc.、Ascenda BioSciences LLC、AstraZeneca, PLC、Becton, Dickinson, and Company、Bio-Rad Laboratories, Inc、Biocept, Inc.、BioNTech SE、C.R. Bard, Inc.、Danaher Corporation、Epigenomics Inc.などの企業情報を掲載しています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の乳がん診断市場規模：技術別 - 画像検査の市場規模 - 分子検査の市場規模 - 組織生検検査の市場規模 ・世界の乳がん診断市場規模：がん種類別 - BRCA乳がんの市場規模 - EGFR変異検査乳がんの市場規模 - ER＆PR乳がんの市場規模 - HER2乳がんの市場規模 ・世界の乳がん診断市場規模：コンポーネント別 - 消耗品の市場規模 - 器具の市場規模 ・世界の乳がん診断市場規模：エンドユーザー別 - 診断検査室における市場規模 - 病院＆外来手術センターにおける市場規模 - 研究・学術機関における市場規模 ・世界の乳がん診断市場規模：地域別 - 南北アメリカの乳がん診断市場規模 アメリカの乳がん診断市場規模 カナダの乳がん診断市場規模 ブラジルの乳がん診断市場規模 ... - アジア太平洋の乳がん診断市場規模 日本の乳がん診断市場規模 中国の乳がん診断市場規模 インドの乳がん診断市場規模 韓国の乳がん診断市場規模 台湾の乳がん診断市場規模 ... - ヨーロッパ/中東/アフリカの乳がん診断市場規模 イギリスの乳がん診断市場規模 ドイツの乳がん診断市場規模 フランスの乳がん診断市場規模 ロシアの乳がん診断市場規模 ... - その他地域の乳がん診断市場規模 ・競争状況 ・企業情報 |
The Global Breast Cancer Diagnostics Market size was estimated at USD 5,685.81 million in 2021 and expected to reach USD 6,129.25 million in 2022, and is projected to grow at a CAGR 7.97% to reach USD 9,010.75 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Breast Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Technique, the market was studied across Imaging, Molecular Testing, and Tissue Biopsy Tests. The Imaging is further studied across Analog Mammography, Breast Ultrasound System, Digital Mammography, Mammography, MRI Scan, and PET/CT Scan.
Based on Cancer Type, the market was studied across BRCA Breast Cancer, EGFR Mutation Test Breast Cancer, ER & PR Breast Cancer, and HER 2 Breast Cancer.
Based on Component, the market was studied across Consumables and Instruments. The Consumables is further studied across Antibodies, Kits & Reagents, and Probes. The Instruments is further studied across Biopsy Instruments, Imaging Instruments, and Pathology-based Instruments.
Based on Diagnostic Type, the market was studied across Ionizing Breast Imaging Technologies and Non-ionizing Imaging Technologies.
Based on End-user, the market was studied across Diagnostic Laboratories, Hospitals & Ambulatory Surgery Center, and Research & Academic Institutes.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Breast Cancer Diagnostics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Breast Cancer Diagnostics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Breast Cancer Diagnostics Market, including Abbott Laboratories, Agilent Technologies, Inc., Ascenda BioSciences LLC, AstraZeneca, PLC, Becton, Dickinson, and Company, Bio-Rad Laboratories, Inc, Biocept, Inc., BioNTech SE, C.R. Bard, Inc., Danaher Corporation, Epigenomics Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corporation, GE Healthcare, Genomic Health, Hologic Inc., Illumina, Inc., Koninklijke Philips N.V., Leica Biosystems, Myriad Genetics, Inc., NanoString Technologies, Inc, Paragon Biosciences LLC, Questex LLC, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Todos Medical, and Toshiba Corporation.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Breast Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Breast Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Breast Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Breast Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Breast Cancer Diagnostics Market?
6. What is the market share of the leading vendors in the Global Breast Cancer Diagnostics Market?
7. What modes and strategic moves are considered suitable for entering the Global Breast Cancer Diagnostics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of breast cancer
5.1.1.2. Favourable reimbursement framework for breast cancer diagnosis
5.1.1.3. Growing number of breast cancer screening programs
5.1.2. Restraints
5.1.2.1. Dearth of the skilled and trained professionals
5.1.3. Opportunities
5.1.3.1. Technological advancements such as introduction of hybrid imaging technique
5.1.3.2. Focus on development of effective diagnostic
5.1.4. Challenges
5.1.4.1. Ignorance of the prediagnostic symptoms
5.2. Cumulative Impact of COVID-19
6. Breast Cancer Diagnostics Market, by Technique
6.1. Introduction
6.2. Imaging
6.3.1. Analog Mammography
6.3.2. Breast Ultrasound System
6.3.3. Digital Mammography
6.3.4. Mammography
6.3.5. MRI Scan
6.3.6. PET/CT Scan
6.3. Molecular Testing
6.4. Tissue Biopsy Tests
7. Breast Cancer Diagnostics Market, by Cancer Type
7.1. Introduction
7.2. BRCA Breast Cancer
7.3. EGFR Mutation Test Breast Cancer
7.4. ER & PR Breast Cancer
7.5. HER 2 Breast Cancer
8. Breast Cancer Diagnostics Market, by Component
8.1. Introduction
8.2. Consumables
8.3.1. Antibodies
8.3.2. Kits & Reagents
8.3.3. Probes
8.3. Instruments
8.4.1. Biopsy Instruments
8.4.2. Imaging Instruments
8.4.3. Pathology-based Instruments
9. Breast Cancer Diagnostics Market, by Diagnostic Type
9.1. Introduction
9.2. Ionizing Breast Imaging Technologies
9.3. Non-ionizing Imaging Technologies
10. Breast Cancer Diagnostics Market, by End-user
10.1. Introduction
10.2. Diagnostic Laboratories
10.3. Hospitals & Ambulatory Surgery Center
10.4. Research & Academic Institutes
11. Americas Breast Cancer Diagnostics Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific Breast Cancer Diagnostics Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa Breast Cancer Diagnostics Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.1.1. Quadrants
14.1.2. Business Strategy
14.1.3. Product Satisfaction
14.2. Market Ranking Analysis, By Key Player
14.3. Market Share Analysis, By Key Player
14.4. Competitive Scenario
14.4.1. Merger & Acquisition
14.4.2. Agreement, Collaboration, & Partnership
14.4.3. New Product Launch & Enhancement
14.4.4. Investment & Funding
14.4.5. Award, Recognition, & Expansion
15. Company Usability Profiles
15.1. Abbott Laboratories
15.1.1. Business Overview
15.1.2. Key Executives
15.1.3. Product & Services
15.2. Agilent Technologies, Inc.
15.2.1. Business Overview
15.2.2. Key Executives
15.2.3. Product & Services
15.3. Ascenda BioSciences LLC
15.3.1. Business Overview
15.3.2. Key Executives
15.3.3. Product & Services
15.4. AstraZeneca, PLC
15.4.1. Business Overview
15.4.2. Key Executives
15.4.3. Product & Services
15.5. Becton, Dickinson, and Company
15.5.1. Business Overview
15.5.2. Key Executives
15.5.3. Product & Services
15.6. Bio-Rad Laboratories, Inc
15.6.1. Business Overview
15.6.2. Key Executives
15.6.3. Product & Services
15.7. Biocept, Inc.
15.7.1. Business Overview
15.7.2. Key Executives
15.7.3. Product & Services
15.8. BioNTech SE
15.8.1. Business Overview
15.8.2. Key Executives
15.8.3. Product & Services
15.9. C.R. Bard, Inc.
15.9.1. Business Overview
15.9.2. Key Executives
15.9.3. Product & Services
15.10. Danaher Corporation
15.10.1. Business Overview
15.10.2. Key Executives
15.10.3. Product & Services
15.11. Epigenomics Inc
15.11.1. Business Overview
15.11.2. Key Executives
15.11.3. Product & Services
15.12. F. Hoffmann-La Roche Ltd
15.12.1. Business Overview
15.12.2. Key Executives
15.12.3. Product & Services
15.13. FUJIFILM Holdings Corporation
15.13.1. Business Overview
15.13.2. Key Executives
15.13.3. Product & Services
15.14. GE Healthcare
15.14.1. Business Overview
15.14.2. Key Executives
15.14.3. Product & Services
15.15. Genomic Health
15.15.1. Business Overview
15.15.2. Key Executives
15.15.3. Product & Services
15.16. Hologic Inc.
15.16.1. Business Overview
15.16.2. Key Executives
15.16.3. Product & Services
15.17. Illumina, Inc.
15.17.1. Business Overview
15.17.2. Key Executives
15.17.3. Product & Services
15.18. Koninklijke Philips N.V.
15.18.1. Business Overview
15.18.2. Key Executives
15.18.3. Product & Services
15.19. Leica Biosystems
15.19.1. Business Overview
15.19.2. Key Executives
15.19.3. Product & Services
15.20. Myriad Genetics, Inc.
15.20.1. Business Overview
15.20.2. Key Executives
15.20.3. Product & Services
15.21. NanoString Technologies, Inc
15.21.1. Business Overview
15.21.2. Key Executives
15.21.3. Product & Services
15.22. Paragon Biosciences LLC
15.22.1. Business Overview
15.22.2. Key Executives
15.22.3. Product & Services
15.23. Questex LLC
15.23.1. Business Overview
15.23.2. Key Executives
15.23.3. Product & Services
15.24. Siemens Healthineers AG
15.24.1. Business Overview
15.24.2. Key Executives
15.24.3. Product & Services
15.25. Thermo Fisher Scientific Inc.
15.25.1. Business Overview
15.25.2. Key Executives
15.25.3. Product & Services
15.26. Todos Medical
15.26.1. Business Overview
15.26.2. Key Executives
15.26.3. Product & Services
15.27. Toshiba Corporation
15.27.1. Business Overview
15.27.2. Key Executives
15.27.3. Product & Services
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing